Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus anlotinib after first-line immunotherapy failure in advanced NSCLC
ChiCTR2000035666Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Target lesion response. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
nivolumabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000035666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035666.